Drugs / Vectibix®
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | VECTIBIX | — | 2008-06-23 – 2025-01-16 | fda.gov ↗ |
| Approved | EU (EMA) | Vectibix | — | 2007-12-03 | europa.eu ↗ |
| Approved | US (FDA) | VECTIBIX | — | 2006-09-27 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04234594 Comparator | Oct 2019 → Sep 2020 | — | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vectibix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04234594 ↗ |
| Route | Intravenous | “6 mg/kg intravenous (IV) infusion only once，on the first day.” NCT04234594 ↗ |